A Phase 1/2 interventional study of ATL001 and Checkpoint Inhibitor in Melanoma, sponsored by Achilles Therapeutics UK Limited. Terminated at 10 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-07.
Sponsored by Achilles Therapeutics UK Limited · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 269 studies in Melanoma with a site in United Kingdom — 31 open to participants now, 73 under way, 24 of them phase 3. Melanoma · United Kingdom.
Among the 269 studies in Melanoma with a site in United Kingdom, this one is the 208th largest by enrollment of the 226 interventional ones that give a count, is one of 15 that started in 2019, is one of 35 in phase 1/2, and was the 165th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →31 of the 269 studies in Melanoma with a site in United Kingdom are open now. Recruiting first, the newest first:
Institute of Cancer Research, United Kingdom · Sites in United Kingdom
Ages 18+
Mitra Bio · Sites in United Kingdom, Belgium, Germany and 1 more country
Ages 18+
IDEAYA Biosciences · Sites in United Kingdom, United States, Australia and 18 more countries
Ages 18+
Cancer Research UK · Sites in United Kingdom
Melanoma Institute Australia · Sites in United Kingdom, United States, Australia and 3 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
269 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 70 · Phase 2 108 · Phase 3 80
First in 1989; this study’s year is marked. 15 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 183 across the 226 interventional studies, 400 across the 41 observational. Of the 172 that completed or were terminated, 96 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
193 of 269 have an industry lead sponsor. The 10 most frequent:
Achilles Therapeutics UK Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.
Achilles Therapeutics UK Limited has 2 studies filed under Melanoma — fewer than ten, so there is no comparison to draw.
14 of the studies in Melanoma with a site in United Kingdom that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05608291Phase 3Regeneron PharmaceuticalsA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | 2027-01-15 |
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT05270044Phase 3Pierre Fabre MedicamentAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. | 2027-03-31 |
| NCT05522660Phase 3ETOP IBCSG Partners FoundationImmunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer | 2027-06 |
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
Add all 14 to your calendar (.ics) → With an account.
Among the 269 studies in Melanoma with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma.
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with metastatic or recurrent melanoma.
Patients will initially enter the study for procurement of tumour materials required to manufacture ATL001.Following manufacture of ATL001, the product will be given back to eligible patients following lymphodepletion.
Patients will be followed up for a period of 24 months post ATL001 infusion in the study.
Patients will continue to be followed up for a minimum of 5 years, as part of a separate Long Term Follow Up Protocol, or, if the separate protocol is not available at the study site, within this protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional Exclusion criteria will apply as per the study protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following lymphodepletion, infusion of cell therapy product ATL001, followed by a low dose regimen of IL- 2.
Biological: ATL001
Following lymphodepletion, infusion of cell therapy product ATL001 in combination with a checkpoint inhibitor, followed by a low dose regimen of IL-2.
Biological: ATL001 · Drug: Checkpoint Inhibitor
Following lymphodepletion, infusion of cell therapy product ATL001, followed by a higher dose regimen of IL-2.
Biological: ATL001
ATL001 infusion
Nivolumab
This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.
Assessment of Treatment Emergent Adverse Events to Evaluate Safety and Tolerability: CTCAE
Evaluate treatment-emergent adverse events (TEAEs) and serious AEs, per CTCAE, by incidence, severity and relationship to ATL001
Time frame: 60 months due to early termination
Disease Assessment for Change From Baseline in Tumour Size
Evaluate the clinical activity of ATL001 in patients with recurrent or metastatic melanoma using change from baseline in tumour size at week 6, week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR).
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Disease Assessment for Overall Response Rate
Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.
Time frame: Every 6 weeks for 6 months, then every 3 months (up to 60 months due to early study termination)
Disease Assessment for Time to Response and Duration of Response
Evaluate the endpoints of time to response and duration of response (DOR) by the investigator and ICR, per RECIST v1.1 and im-RECIST.
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Disease Assessment for Disease Control Rate
Evaluate the endpoints of disease control rate (DCR) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Disease Assessment for Progression-Free Survival
Evaluate the efficacy endpoints of progression-free survival (PFS) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
Overall Survival
Evaluate overall survival (OS) by investigator
Time frame: Every 6 weeks for 6 months, then every 3 months for a maximum of 84 months
| Milestone | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Started | 9 | 2 | 2 |
| Completed | 0 | 0 | 0 |
| Not completed | 9 | 2 | 2 |
| Withdrew: Death | 6 | 2 | 1 |
| Withdrew: Physician decision | 2 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 | 1 |
Evaluate treatment-emergent adverse events (TEAEs) and serious AEs, per CTCAE, by incidence, severity and relationship to ATL001
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| TEAEs | 9 | 2 | 2 |
| TEAEs related to any component of study treatment | 8 | 2 | 2 |
| Lymphodepletion related TEAEs | 8 | 1 | 2 |
| ATL001 related TEAEs IL-2 related TEAEs Serious TEAEs | 5 | 2 | 2 |
| IL-2 related TEAEs | 7 | 2 | 2 |
| Nivolumab related TEAEs | 0 | 0 | 0 |
| Serious TEAEs | 3 | 1 | 0 |
| Serious TEAEs related to any component of study treatment | 1 | 1 | 0 |
| Serious Lymphodepletion related TEAEs | 0 | 0 | 0 |
| Serious ATL001 related TEAEs | 1 | 1 | 0 |
| Serious IL-2 related TEAEs | 1 | 1 | 0 |
| Serious Nivolumab related TEAEs | 0 | 0 | 0 |
| TEAEs with CTCAE grade >= 3 | 6 | 2 | 1 |
| TEAEs with CTCAE grade >= 3 related to any component of study treatment | 5 | 2 | 1 |
| Lymphodepletion related TEAEs with CTCAE grade >= 3 | 4 | 1 | 1 |
| ATL001 related TEAEs with CTCAE grade >= 3 | 2 | 1 | 0 |
| IL-2 related TEAEs with CTCAE grade >= 3 | 2 | 2 | 0 |
| Nivolumab related TEAEs with CTCAE grade >= 3 | 0 | 1 | 0 |
| TEAEs leading to death | 0 | 1 | 0 |
| TEAEs leading to death related to any component of study treatment | 0 | 0 | 0 |
| SAEs | 3 | 2 | 1 |
Evaluate the clinical activity of ATL001 in patients with recurrent or metastatic melanoma using change from baseline in tumour size at week 6, week 12 and best overall change from baseline, as assessed by investigator and independent central review (ICR).
Results for this outcome have not been posted.
Evaluate the endpoint of overall response rate (ORR), as assessed by investigator and ICR, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and immune modified RECIST( im-RECIST). RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) is a standardized system for measuring tumor response to treatment in clinical trials. Tumors are assessed by imaging (e.g., CT or MRI) based on changes in size. Responses are categorized as: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): ≥30% reduction in the sum of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD). Progressive Disease (PD): ≥20% increase in the sum of target lesions, or appearance of new lesions. These criteria help assess the efficacy of treatments in solid tumors supported by im-RECIST in immunotherapy.
| Participants | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Responders | 0 | 0 | 0 |
| Non-Responders | 9 | 2 | 2 |
Evaluate the endpoints of time to response and duration of response (DOR) by the investigator and ICR, per RECIST v1.1 and im-RECIST.
Results for this outcome have not been posted.
Evaluate the endpoints of disease control rate (DCR) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.
Results for this outcome have not been posted.
Evaluate the efficacy endpoints of progression-free survival (PFS) as assessed by the investigator and ICR per RECIST v1.1 and im-RECIST.
Results for this outcome have not been posted.
Evaluate overall survival (OS) by investigator
Results for this outcome have not been posted.
Collected over Each patient that received ATL001 would have been followed up for 24 months, to withdrawal of consent or death. Patients would then continue to be followed up for a minimum of 5 years as part of long term follow up. The study was terminated early due to sponsor decision. The Median follow-up period was 12 weeks (range: 3 - 48 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A | 8/9 (88.9%) | 3/9 (33.3%) | 9/9 (100%) |
| Cohort B | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) |
| Cohort C | 1/2 (50%) | 1/2 (50%) | 2/2 (100%) |
| Event | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 0/9 | 0/2 | 1/2 |
| Immune effector cell-associated neurotoxicity syndromeNervous system disorders | 1/9 | 1/2 | 0/2 |
| Adrenal insufficiencyEndocrine disorders | 0/9 | 1/2 | 0/2 |
| Pneumonia aspirationInfections and infestations | 0/9 | 1/2 | 0/2 |
| SepsisInfections and infestations | 2/9 | 0/2 | 0/2 |
| Abdominal wall infectionInfections and infestations | 1/9 | 0/2 | 0/2 |
| Klebsiella sepsisInfections and infestations | 1/9 | 0/2 | 0/2 |
| ConstipationGastrointestinal disorders | 1/9 | 0/2 | 0/2 |
| Drain site complicationInjury, poisoning and procedural complications | 1/9 | 0/2 | 0/2 |
| HaematuriaRenal and urinary disorders | 1/9 | 0/2 | 0/2 |
| Event | Cohort A | Cohort B | Cohort C |
|---|---|---|---|
| FatigueGeneral disorders | 3/9 | 1/2 | 2/2 |
| AnaemiaBlood and lymphatic system disorders | 4/9 | 2/2 | 2/2 |
| ConstipationGastrointestinal disorders | 3/9 | 2/2 | 1/2 |
| NauseaGastrointestinal disorders | 6/9 | 2/2 | 1/2 |
| Lymphocyte count decreasedInvestigations | 3/9 | 2/2 | 0/2 |
| FallInjury, poisoning and procedural complications | 0/9 | 2/2 | 0/2 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/9 | 2/2 | 0/2 |
| NeutropeniaBlood and lymphatic system disorders | 7/9 | 0/2 | 1/2 |
| PyrexiaGeneral disorders | 6/9 | 1/2 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 5/9 | 1/2 | 0/2 |
No differences.
| Age, Categorical(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 8 | 2 | 2 | 12 |
| >=65 years | 1 | 0 | 0 | 1 |
| Age, Continuous(years) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Mean | 50.4 ± 10.49 | 59.5 ± 4.95 | 36.5 ± 4.95 | 49.7 ± 11.09 |
| Sex: Female, Male(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Female | 2 | 0 | 2 | 4 |
| Male | 7 | 2 | 0 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 9 | 2 | 2 | 13 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 9 | 2 | 2 | 13 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| United Kingdom | 9 | 2 | 1 | 12 |
| Spain | 0 | 0 | 1 | 1 |
| Body mass index (kg/m^2)(kg/m^2) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Mean | 28.52 ± 4.922 | 25.55 ± 2.052 | 22.90 ± 1.838 | 27.2 ± 4.651 |
| Baseline ECOG performance status(Participants) | Cohort A | Cohort B | Cohort C | Total |
|---|---|---|---|---|
| Grade 0 | 2 | 1 | 1 | 4 |
| Grade 1 | 7 | 1 | 1 | 9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Sep 2024, 60 months.
Results were first posted in Mar 2025, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Autologous Clonal Neoantigen T Cells ATL001
Achilles Therapeutics UK Limited